Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Reduced mortality with low-dose rivaroxaban in patients with coronary artery disease: a meta-analysis.

Created on 21 Nov 2026

Authors

Tullio Palmerini, Elena Nardi, Matteo Lezzi, Antonio G Bruno, Laura Lombardi, Gerald Chi, Nevio Taglieri, Gabriele Ghetti, Mateusz Orzalkiewicz, Francesco Saia, Mattia Galli, C Michael Gibson

Published in

The Journal of invasive cardiology. Nov 20, 2026. Epub Nov 20, 2026.

Abstract

The optimal antithrombotic therapy (ATT) for patients with coronary artery disease (CAD) is still a matter of debate. In this regard, the role of low-dose rivaroxaban remains controversial. The authors performed a meta-analysis of randomized controlled trials (RCT) comparing low-dose rivaroxaban vs standard ATT across the spectrum of CAD.
RCTs were searched through MEDLINE, EMBASE, and Cochrane databases, and international meeting proceedings. The primary endpoint was all-cause mortality. Results are reported as incidence rate ratio (IRR) of low-dose rivaroxaban vs standard ATT.
Five trials including 37 709 randomized patients were identified. Low-dose rivaroxaban was associated with significantly lower rates of all-cause mortality (IRR = 0.83; 95% CI, 0.70-0.98; P = .02), driven by a significant reduction in cardiovascular mortality (IRR = 0.82; 95% CI, 0.69-0.97; P = .02). Low-dose rivaroxaban was also associated with a significant reduction in myocardial infarction (IRR = 0.88; 95% CI, 0.79-0.99; P = .04), major adverse cardiovascular events (IRR = 0.85; 95% CI, 0.76-0.95; P less than .01), and stroke (IRR = 0.71; 95% CI, 0.55-0.91; P less than .01). Stroke reduction was driven by a significant reduction in ischemic strokes (IRR = 0.60; 95% CI, 0.49-0.74; P less than .01), not offset by an increase in hemorrhagic strokes. In contrast, low-dose rivaroxaban increased major bleeding (IRR = 1.46; 95% CI, 0.99-2.17), but not fatal bleeding.
In patients with CAD, low-dose rivaroxaban significantly reduces all-cause mortality, cardiovascular mortality, and stroke, but increases major bleeding compared with standard ATT.

PMID:
43063510
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement